M

Mitsubishi Chemical Group Corp
F:M3C0

Watchlist Manager
Mitsubishi Chemical Group Corp
F:M3C0
Watchlist
Price: 29 EUR Market Closed
Market Cap: €8.3B

Mitsubishi Chemical Group Corp
Investor Relations

Mitsubishi Chemical Group Corporation, a cornerstone of Japan’s industrial landscape, intricately weaves its operations across a spectrum of chemical and material science sectors. As the flagship of Mitsubishi’s chemical subsidiaries, it has crafted a robust portfolio that underscores its dedication to innovation and sustainability. The company’s reach extends globally, leveraging research and development to pioneer advanced solutions in fields like performance products, industrial materials, and health care. By strategically aligning its resources to address the ever-evolving demands of these dynamic industries, Mitsubishi Chemical has positioned itself as a key player at the intersection of tradition and innovation.

The powerhouse generates revenue through a diversified approach, integrating its activities from core chemicals to customized solutions tailored for clients across various sectors. Mitsubishi’s business spans the production of petrochemicals and carbon products, leading to advanced polymers and functional materials for electronics and automotive industries, showcasing its ability to adapt and thrive in a competitive marketplace. Additionally, its ventures into healthcare and life sciences reflect an acute awareness of global trends and the needs of an aging population, indicating a commitment to long-term sustainable growth. By capturing the synergy of its operations, Mitsubishi Chemical not only delivers essential materials but also positions itself as a provider of solutions, ensuring its continued relevance and economic success.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2026
Call Date
Feb 5, 2026
AI Summary
Q3 2026

Revenue Decline: Revenue for the first nine months was JPY 2,737.3 billion, down 8% year-on-year due to lower prices, volumes, and business restructuring.

Profit Drop & Nonrecurring Losses: Core operating income decreased 2% year-on-year to JPY 185.6 billion, with net income boosted by proceeds from Mitsubishi Tanabe Pharma sale but offset by a major nonrecurring loss from exiting coke and carbon materials businesses.

Guidance Cut: Full-year profit attributable to owners forecast was sharply revised down from JPY 125 billion to JPY 47 billion due to anticipated additional nonrecurring losses.

Dividend Unchanged: The company maintained its dividend guidance of JPY 16 per share year-end, JPY 32 for the year.

Industrial Gases Outperform: Industrial Gases segment showed steady growth, outperforming internal expectations.

Structural Reforms: Portfolio restructuring continues, with withdrawal from carbon and coke materials and preparations for further announcements on petrochemicals and MMA by March.

Specialty Materials Resilient: Specialty Materials outperformed with higher profits despite revenue decline, driven by rationalization and higher selling prices.

Carbon Composites Growth: Significant ramp-up in carbon composites production and shipments expected from fiscal 2026, contributing more to profits.

Key Financials
Revenue
JPY 2,737.3 billion
Core Operating Income
JPY 185.6 billion
Profit Attributable to Owners of the Parent
JPY 105.4 billion
Operating Income
JPY 113.3 billion
Special Items
net loss of JPY 72.3 billion
Net Income from Discontinued Operations
JPY 94.8 billion
Free Cash Flow
JPY 370.8 billion
Dividend
JPY 16 per share year-end, JPY 32 per share annual
Net Interest-Bearing Debt
decreased by JPY 324 billion from previous year end
Net D/E Ratio
0.83
Core Operating Income (Chemicals segment)
JPY 41.2 billion (first 9 months)
Other Earnings Calls

Management

Mr. Ken Fujiwara
Executive VP, General Counsel & Director
No Bio Available
Frank Randall Queen
Executive VP & Head of Specialty Materials
No Bio Available
Mr. Manabu Chikumoto
President, CEO, Representative Corporate Executive Officer & Director
No Bio Available
Mr. Minoru Kida
VP & CFO
No Bio Available
Toshiya Katsuragi
Senior VP & CTO
No Bio Available
Isao Yano
Senior VP & Chief Compliance Officer
No Bio Available
Mr. Osamu Shimizu
General Manager of Corporate Communications Office
No Bio Available
Masahiko Tanaka
VP & Chief Human Resource Officer
No Bio Available
Mr. Yuji Ichimura
Senior VP & Chief Digital Officer
No Bio Available
Mr. Akihiro Tsujimura M.B.A.
Executive VP & Head of Pharma
No Bio Available

Contacts

Address
TOKYO-TO
Chiyoda-ku
Palace Bldg., 1-1-1, Marunouchi
Contacts
+81367487200
www.mcgc.com